Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/9/2008

is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward- looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost- effective clinical trials or meet, as anticipated, the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... MA (PRWEB) July 28, 2014 Immunomic ... two researchers to further develop potential treatments for glioblastoma ... tumor, in combination with their patented vaccine platform, LAMP-vax. ... Duke University, are based on the work of John ... Neurosurgery at The Preston Robert Tisch Brain Tumor Center ...
(Date:7/28/2014)... It’s a hard truth: Nearly half of recent ... post-secondary education are failing to obtain a diploma or certificate ... according to an analysis by The Resume Place , ... choice of college majors, which leads to underemployment, unemployment or ... 51.7 percent of post-9/11 veterans using GI Bill ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4
... Veracyte, Inc ., a molecular diagnostics company pioneering the ... of Mark Spring as chief financial officer. ... the Veracyte team," said Bonnie Anderson, Veracyte,s cofounder and ... and senior finance leader in both public and private ...
... Calif., Jan. 26, 2012 Cepheid (Nasdaq: CPHD ... of $80.1 million.  Net loss was $1.6 million, or $(0.03) ... net income of $1.3 million, or $0.02 per diluted share, ... quarter net loss reflected a one-time, non-cash charge to cost ...
... Lend Lease is pleased to announce the appointment of ... Sciences group in the Atlantic Region.  Tom rejoined Lend ... of the Raleigh, NC office, working closely with the regional ... Atlantic offices. He will report directly to Steve Eberling, ...
Cached Biology Technology:Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 2Cepheid Reports Fourth Quarter and Full Year 2011 Results 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 4Cepheid Reports Fourth Quarter and Full Year 2011 Results 5Cepheid Reports Fourth Quarter and Full Year 2011 Results 6Cepheid Reports Fourth Quarter and Full Year 2011 Results 7Cepheid Reports Fourth Quarter and Full Year 2011 Results 8Cepheid Reports Fourth Quarter and Full Year 2011 Results 9Cepheid Reports Fourth Quarter and Full Year 2011 Results 10Cepheid Reports Fourth Quarter and Full Year 2011 Results 11Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region 2
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... "big data," a single computer cannot always find the ... distributed across a cluster of computers that analyze a ... mine your web history to present you with targeted ... favorite book or movie. But big data is about ... monitoring brain activity are generating unprecedented quantities of information. ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... research suggests a higher-protein, lower-carbohydrate energy-restricted diet has a ... and increasing lean muscle, particularly when the proteins come ... September issue of the Journal of Nutrition, ... healthy, premenopausal women. Each consumed either low, medium ...
... wastewater recycling processes may generate more greenhouse gases than ... reasons to continue keep wastewater recycling among the water-resource ... of a new paper by Amy Townsend-Small, assistant professor ... and a team of researchers from the University of ...
... whizzes at learning a second language, but that ability begins ... at the University of Washington,s Institute for Learning & Brain ... prowess at learning languages, with the hope that the findings ... study, the researchers report that the brains of babies raised ...
Cached Biology News:Foods rich in protein, dairy products help dieters preserve muscle and lose belly fat: study 2Wastewater recycling can multiply greenhouse gas emissions 2Wastewater recycling can multiply greenhouse gas emissions 3Bilingual babies' vocabulary linked to early brain differentiation 2Bilingual babies' vocabulary linked to early brain differentiation 3
... PCRx Enhancer System is ... polymerases to optimize PCR of ... 10X PCRX Enhancer Solution with ... higher primer specificity broader magnesium ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Mouse Exodus 2 - 12kDa...
Fibulin-2 (D-15)...
Biology Products: